Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Liver Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
13 drugs · 38 active trials
14 drugs · 333 active trials
Outside the funnel: Phase not stated 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 7, 2023 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-11 |
| Onatasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 20, 2010 |
| Pasireotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-12 |
| Pemetrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-01 |
| Porfimer | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1999-03 |
| Refametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 16, 2013 |
| Ribociclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2016-04 |
| Tepotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 6, 2014 |
| Topotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1992-10 |
| Abemaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 31, 2019 |
| Amivantamab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 8, 2022 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Enasidenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 8, 2014 |
| Hydroxyurea | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-03 |
| Linsitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 10, 2011 |
| Lonafarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-10 |
| Peginterferon Alfa-2a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-01 |
| Prednisolone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Ropeginterferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 12, 2019 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 5, 2016 |
| Tamibarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-07 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-07 |
| Vorinostat | Phase 1 | Phase 1 | 1 | 1 | 0 | 5 | 0 | — | — | 2006-11 |
| Azacitidine | Phase 1 | Phase 1 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-05 |
| Carfilzomib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 4, 2026 |
| Exemestane | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 15, 2025 |
| Lifileucel | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | May 27, 2020 |
| O6-Benzylguanine | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2000-06 |
| Aflibercept | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 18, 2014 |
| Duvelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 3, 2022 |
| FGFR4 Inhibitor H3B-6527 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 28, 2016 |
| Fisogatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 31, 2015 |
| Foretinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2009 |
| Ganetespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-08 |
| HDAC Inhibitor REC-2282 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 4, 2010 |
| Interferon Alfacon-1 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-07 |
| MTOR Kinase Inhibitor AZD8055 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-10 |
| Onartuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-09 |
| Pralsetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 2, 2017 |
| Retifanlimab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 3, 2021 |
| Carmustine | Phase not stated | N/A | 0 | 0 | 0 | 2 | 0 | — | — | Jun 29, 2006 |
| Anti-PD1 Monoclonal Antibody | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | Mar 20, 2024 |
| Plerixafor | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.